Spruce 10-Q: $24M Q3 Loss, $87.7M Cash, Going-Concern Warning Ahead of December BLA
SPRB sits 18% above its 52-week low of $38.06.
Summary
Spruce's Q3 10-Q shows a $24.0 million quarterly loss and $87.7 million of cash that management says will not last twelve months, putting going-concern language in print just weeks before the planned December 2026 TA-ERT BLA submission.
Key Events · Earnings and Guidance · SPRB
-
Q3 Loss Widens on TA-ERT Spend
Net loss was $24.0 million, or $(8.51) per share, versus $8.2 million a year ago; R&D rose to $18.1 million from $5.0 million on TA-ERT manufacturing and clinical development.
-
Going-Concern Doubt Disclosed
Management states $87.7 million of cash at September 30, 2026 will be insufficient to fund planned operations and debt obligations for at least 12 months, raising substantial doubt about the ability to continue as a going concern.
-
Avenue Tranche 2 Upsized but Gated
The November 6, 2026 amendment raises Tranche 2 to up to $15.0 million, drawable only between January 1 and March 31, 2027 subject to conditions, and extends the interest-only period through March 31, 2027; principal payments begin April 2027 absent further extension.
-
December BLA and Adrenyx Spin Ahead
Spruce still targets a December 2026 BLA submission for TA-ERT and expects to complete the Adrenyx distribution in the first half of 2027, with Adrenyx holding a separate $10.0 million convertible note facility of which $5.0 million was funded at closing.
Analysis · SPRB · Life Sciences
The quarter was already public this morning, but the 10-Q carries the piece the 8-K summary did not: management states plainly that $87.7 million of cash will not fund operations and debt obligations for the next twelve months, so substantial doubt about going concern exists. That matters because the company is simultaneously spending heavily to file a BLA for TA-ERT in December 2026 and to stand up manufacturing, with R&D up to $18.1 million in the quarter from $5.0 million a year ago. The Avenue facility is the near-term lifeline — Tranche 2 was upsized to $15.0 million but cannot be drawn until January 1, 2027, and only if conditions are met, while principal payments start in April 2027 absent a further extension. A capital raise, a priority review voucher sale, or a partnership is required, and any equity route dilutes holders at a share count of just 2.87 million.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SPRB was trading at $45.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $38.06 to $129.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.